Neurology 2000;54:1145-1155
© 2000 American Academy of Neurology
Articles
Cladribine and progressive MS
Clinical and MRI outcomes of a multicenter controlled trial
George P. A. Rice, MD,
Massimo Filippi, MD,
Giancarlo Comi, MD and
for the Cladribine Clinical Study Group* and for the Cladribine MRI Study Group,*
From the University Hospital (Dr. Rice), University of Western Ontario, London, Canada; and the Neuroimaging Research Unit (Dr. Filippi) and Clinical Trials Unit (Dr. Comi), Department of Neuroscience, Scientific Institute Ospedale San Raffaele, University of Milan, Italy.
Address correspondence and reprint requests to Dr. Rice, LHSC-UC, 339 Windermere Road, London, Ontario N6A 5A5, Canada; e-mail: grice{at}julian.uwo.ca
OBJECTIVE: To evaluate the safety and efficacy of two doses of cladribine in patients with progressive MS.
BACKGROUND: Treatment of progressive MS patients with cladribine in a previous single-center, placebo-controlled clinical trial was associated with disease stabilization.
METHODS: In the current study, 159 patients with a median baseline Kurtzke’s Expanded Disability Status Scale (EDSS) score of 6.0 were randomly assigned to receive placebo or cladribine 0.07 mg/kg/day for 5 consecutive days every 4 weeks for either two or six cycles (total dose, 0.7 mg/kg or 2.1 mg/kg, respectively), followed by placebo, for a total of eight cycles. Thirty percent had primary progressive MS (PPMS) and 70% had secondary progressive MS (SPMS). EDSS and Scripps Neurologic Rating Scale (SNRS) scores were assessed bimonthly and MRI was performed every 6 months. The primary outcome measure was disability (mean change in EDSS).
RESULTS: Mean changes in disability did not differ among the groups at the end of the 12-month double-blind phase. Both cladribine treatments were superior to placebo for the proportion of patients having gadolinium-enhanced T1 lesions and for the mean volume and number of such lesions (p  0.003). Differences were statistically significant at the 6-month evaluation time, with  90% reduction in volume and number of enhanced T1 lesions, which was maintained through final evaluation. This effect segregated largely with the SPMS group. The T2 burden of disease showed a modest improvement in cladribine-treated patients and worsened in placebo-treated patients. Most adverse events were mild or moderate in severity and not treatment limiting.
CONCLUSION: No significant treatment effects were found for cladribine in terms of changes in EDSS or SNRS scores. Both doses of cladribine produced and sustained significant reductions in the presence, number, and volume of gadolinium-enhanced T1 brain lesions on MRI, and cladribine 2.1 mg/kg reduced the accumulation of T2 lesion load. Cladribine at doses up to 2.1 mg/kg was generally safe and well tolerated.
Key words: Cladribine—MRI—Progressive MS—Suppression of disease activity.
This article has been cited by other articles:
|
|
|
|
 
G. Giovannoni, G. Comi, S. Cook, K. Rammohan, P. Rieckmann, P. S. Sorensen, P. Vermersch, P. Chang, A. Hamlett, B. Musch, et al.
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
N. Engl. J. Med.,
February 4, 2010;
362(5):
416 - 426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. W. Rammohan and J. Shoemaker
Emerging multiple sclerosis oral therapies
Neurology,
January 5, 2010;
74(1_Supplement_1):
S47 - S53.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Cohen
Emerging Therapies for Relapsing Multiple Sclerosis
Arch Neurol,
July 1, 2009;
66(7):
821 - 828.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z Stelmasiak, J Solski, J Nowicki, B Jakubowska, M Ryba, and P Grieb
Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study
Multiple Sclerosis,
June 1, 2009;
15(6):
767 - 770.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D Bar-Zohar, F Agosta, D Goldstaub, and M Filippi
Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives
Multiple Sclerosis,
July 1, 2008;
14(6):
719 - 727.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Maier, A. V. Kuhnert, N. Taheri, M. B. Sattler, M. K. Storch, S. K. Williams, M. Bahr, and R. Diem
Effects of Glatiramer Acetate and Interferon-{beta} on Neurodegeneration in a Model of Multiple Sclerosis: A Comparative Study
Am. J. Pathol.,
October 1, 2006;
169(4):
1353 - 1364.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A Brousil, R. J Roberts, and A. L Schlein
Cladribine: An Investigational Immunomodulatory Agent for Multiple Sclerosis
Ann. Pharmacother.,
October 1, 2006;
40(10):
1814 - 1821.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Paintlia, M. K. Paintlia, I. Singh, and A. K. Singh
Immunomodulatory Effect of Combination Therapy with Lovastatin and 5-Aminoimidazole-4-Carboxamide-1-{beta}-D-Ribofuranoside Alleviates Neurodegeneration in Experimental Autoimmune Encephalomyelitis
Am. J. Pathol.,
September 1, 2006;
169(3):
1012 - 1025.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Compston
Making progress on the natural history of multiple sclerosis.
Brain,
March 1, 2006;
129(Pt 3):
561 - 563.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kremenchutzky, G. P. A. Rice, J. Baskerville, D. M. Wingerchuk, and G. C. Ebers
The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease
Brain,
March 1, 2006;
129(3):
584 - 594.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. A. Ioannidis
Contradicted and Initially Stronger Effects in Highly Cited Clinical Research
JAMA,
July 13, 2005;
294(2):
218 - 228.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Cohen and J. P. Antel
Does interferon beta help in secondary progressive MS?
Neurology,
November 23, 2004;
63(10):
1768 - 1769.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Kappos, B. Weinshenker, C. Pozzilli, A. J. Thompson, F. Dahlke, K. Beckmann, C. Polman, H. McFarland, and for the European and North American Interferon b
Interferon beta-1b in secondary progressive MS: A combined analysis of the two trials
Neurology,
November 23, 2004;
63(10):
1779 - 1787.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. M. Boneschi, M. Rovaris, G. Comi, and M. Filippi
The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials
Multiple Sclerosis,
August 1, 2004;
10(4):
341 - 347.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D.S. Goodin, B.G. Arnason, P.K. Coyle, E.M. Frohman, and D.W. Paty
The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurology,
November 25, 2003;
61(10):
1332 - 1338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G V McDonnell, J Cabrera-Gomez, D B Calne, D K. Li, and J Oger
Clinical presentation of primary progressive multiple sclerosis 10 years after the incidental finding of typical magnetic resonance imaging brain lesions: The subclinical stage of primary progressive multiple sclerosis may last 10 years
Multiple Sclerosis,
April 1, 2003;
9(2):
204 - 209.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. Lublin
Therapeutic approaches to secondary progressive multiple sclerosis
Multiple Sclerosis,
September 1, 2002;
8(1_suppl):
88 - 90.
[PDF]
|
|
|
|
|
|
|
D. H. Miller, F. Barkhof, J. A. Frank, G. J. M. Parker, and A. J. Thompson
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance
Brain,
August 1, 2002;
125(8):
1676 - 1695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F D Lublin
Therapeutic approaches to secondary progressive multiple sclerosis
Multiple Sclerosis,
February 1, 2002;
8(1):
88 - 90.
[PDF]
|
|
|
|
|
|
|
R. M. Herndon
Medical Hypothesis: Why Secondary Progressive Multiple Sclerosis Is a Relentlessly Progressive Illness
Arch Neurol,
February 1, 2002;
59(2):
301 - 304.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Furlan, E. Brambilla, F. Ruffini, P. L. Poliani, A. Bergami, P. C. Marconi, D. M. Franciotta, G. Penna, G. Comi, L. Adorini, et al.
Intrathecal Delivery of IFN-{gamma} Protects C57BL/6 Mice from Chronic-Progressive Experimental Autoimmune Encephalomyelitis by Increasing Apoptosis of Central Nervous System-Infiltrating Lymphocytes
J. Immunol.,
August 1, 2001;
167(3):
1821 - 1829.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. L. Mancardi, R. Saccardi, M. Filippi, F. Gualandi, A. Murialdo, M. Inglese, M. G. Marrosu, G. Meucci, L. Massacesi, A. Lugaresi, et al.
Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS
Neurology,
July 10, 2001;
57(1):
62 - 68.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
